Neuroblastoma Treatment Market By Drug 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Neuroblastoma Treatment Market
Neuroblastoma Treatment Market: By Drug (Xalkori, Clafen, Vincasar PFS) By Treatment (Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy) & Geography-Forecast (2016-2021)
Report Code : HCR 0302
Updated Date: 07 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Neuroblastoma is the most common type of cancer found in infants. Neuroblastoma is caused as a result of embryonal malignancy of sympathetic nervous system which arises from the neuroblasts. This cancer develops in the nerve tissues of adrenal, chest or spinal cord. Neuroblastoma is classified as a “rare disease” in the U.S. by the National Institute of Health (NIH), and Orphanet in Europe. Neuroblastoma is a cancer which starts in primitive nerve cells. It rarely occurs after age around 10 years. According to America Cancer Society, neuroblastoma accounts for over 7% of the total cancer cases in age group of 0 to 14 years of age. Some of the most common symptoms of the neuroblastoma are firm mass in the abdomen, enlarged stomach, weight, anemia, crankiness, fever, bone pain, bulging eyes, dark circles around the eyes, weakness, and high blood pressure

Neuroblastoma Treatment Market

North America held substantial revenue share of the overall oxygen therapy market The increasing number of product approvals and high R&D investments are the key growth drivers responsible for the largest share of the market in this region. It is followed by Europe in terms of revenue share owing to the presence of favorable government initiatives for improving respiratory care, such as European Committee for Hyperbaric Medicine (ECHM), involved in promoting awareness pertaining to the treatment.This report on global Neuroblastoma Treatmentis segmented on the basis of Neuroblastoma Treatment application, end-use industries using Neuroblastoma Treatment for wide range of end-use applications and market size in various geographical regions.

This report identifies the Neuroblastoma Treatment market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Neuroblastoma Treatment market.

This report segments global neuroblastoma market on the basis of type, procedures, and regional market as follows:
  • On the basis of treatment categories of Neuroblastoma Treatment, this report is segmented into five major treatment. Some of the major treatment covered  in this report are as follows: Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy and Others
  •  On the basis of drug categories of Neuroblastoma Treatment, this report is segmented into five major drugs. Some of the major drugs covered  in this report are as follows: Xalkori (crizotinib),  Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate) and Others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Neuroblastoma Treatment in each of the region.

This report identifies all the major companies operating in the global Neuroblastoma Treatment market. Some of the major companies’ profiles in detail are as follows:
  • Seattle Children’s
  • Cure Search
  • Texas Children’s
  • NANTGE Healthcare
  • Others
1. Neuroblastoma Treatment– Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Neuroblastoma Treatment– Market Forces
   4.1. Drivers
      4.1.1. Rising cases of cancer in infants due to life style related health impacts
   4.2. Opportunities
   4.3. Challenges
      4.3.1. Lower awareness in the developing nations
   4.4. Porter’s Five Forces Analysis
      4.4.1. Bargaining Power of Suppliers
      4.4.2. Bargaining Power of Buyers
      4.4.3. Threat of New Entrants
      4.4.4. Threat of Substitutes
      4.4.5. Degree of Competition
5. Neuroblastoma Treatment– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Neuroblastoma Treatment Market, By Drug
   6.1. Xalkori (crizotinib)
   6.2.  Adriamycin PFS (Doxorubicin Hydrochloride)
   6.3. Clafen (Cyclophosphamide)
   6.4. Vincasar PFS (Vincristine Sulfate)
   6.5. Others
7. Neuroblastoma Treatment Market, By Treatment
   7.1. Surgery
   7.2. Chemotherapy
   7.3. High-dose chemotherapy with stem cell support
   7.4. Monoclonal antibody treatment
   7.5. Radiotherapy
   7.6. Others
8. Neuroblastoma Treatment Market, By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Neuroblastoma Treatment– Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles (Top 10 Companies)
   10.1. Seattle Children’s
   10.2. Cure Search
   10.3. Texas Children’s
   10.4. NANTGE Healthcare
   10.5. Pfizer Inc.
   10.6. GL Pharm Tech Corporation
   10.7. Hôpitaux de ParisOthers
   10.8. Erasmus Medical Center
   10.9. Assistance Publique - Hopitaux de Paris
   10.10. Texas Neurofibromatosis Foundation
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of expert Insights
   11.6. Disclaimer
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll